PL1755674T3 - Wydłużanie przeżycia alloprzeszczepu poprzez inhibowanie aktywności dopełniacza - Google Patents

Wydłużanie przeżycia alloprzeszczepu poprzez inhibowanie aktywności dopełniacza

Info

Publication number
PL1755674T3
PL1755674T3 PL05779924T PL05779924T PL1755674T3 PL 1755674 T3 PL1755674 T3 PL 1755674T3 PL 05779924 T PL05779924 T PL 05779924T PL 05779924 T PL05779924 T PL 05779924T PL 1755674 T3 PL1755674 T3 PL 1755674T3
Authority
PL
Poland
Prior art keywords
allograft
prolongation
survival
complement activity
inhibiting complement
Prior art date
Application number
PL05779924T
Other languages
English (en)
Inventor
Russell P Rother
Hao Wang
Zhen Zhong
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35385551&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1755674(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of PL1755674T3 publication Critical patent/PL1755674T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL05779924T 2004-05-14 2005-05-16 Wydłużanie przeżycia alloprzeszczepu poprzez inhibowanie aktywności dopełniacza PL1755674T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57144404P 2004-05-14 2004-05-14
EP05779924.9A EP1755674B1 (en) 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity
PCT/US2005/017048 WO2005110481A2 (en) 2004-05-14 2005-05-16 Prolongation of survival of an allograft by inhibiting complement activity

Publications (1)

Publication Number Publication Date
PL1755674T3 true PL1755674T3 (pl) 2015-05-29

Family

ID=35385551

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05779924T PL1755674T3 (pl) 2004-05-14 2005-05-16 Wydłużanie przeżycia alloprzeszczepu poprzez inhibowanie aktywności dopełniacza

Country Status (14)

Country Link
US (3) US20090028850A1 (pl)
EP (4) EP3056218A1 (pl)
JP (3) JP5161567B2 (pl)
AU (1) AU2005244012C1 (pl)
CA (1) CA2566716C (pl)
DK (1) DK1755674T3 (pl)
ES (1) ES2528362T3 (pl)
HK (3) HK1201758A1 (pl)
IL (2) IL179240A (pl)
NZ (1) NZ551308A (pl)
PL (1) PL1755674T3 (pl)
PT (1) PT1755674E (pl)
SI (1) SI1755674T1 (pl)
WO (1) WO2005110481A2 (pl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005110481A2 (en) 2004-05-14 2005-11-24 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
RU2445975C2 (ru) * 2006-03-02 2012-03-27 Алексион Фармасьютикалз, Инк. Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
WO2007106585A1 (en) * 2006-03-15 2007-09-20 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement
EP3028716B1 (en) 2006-10-10 2020-09-16 Regenesance B.V. Complement inhibition for improved nerve regeneration
CN109045296A (zh) 2008-11-10 2018-12-21 阿雷克森制药公司 用于治疗补体相关障碍的方法和组合物
US20110110953A1 (en) * 2009-06-29 2011-05-12 Dennis Keith Bishop Compound and method for treatment of chronic transplant rejection
US9066925B2 (en) * 2009-07-02 2015-06-30 Musc Foundation For Research Development Methods of stimulating liver regeneration
US9420770B2 (en) 2009-12-01 2016-08-23 Indiana University Research & Technology Corporation Methods of modulating thrombocytopenia and modified transgenic pigs
US9527912B2 (en) 2010-05-17 2016-12-27 The Board Of Trustees Of The Leland Stanford Junior University Prevention of immunological rejection of transplanted stem cells by leukocyte costimulatory molecule blockade
US10780118B2 (en) 2012-08-20 2020-09-22 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
EP3290922A1 (en) 2013-08-07 2018-03-07 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
EP3033093A1 (en) 2013-08-16 2016-06-22 Alexion Pharmaceuticals, Inc. Treatment of graft rejection by administering a complement inhibitor to an organ prior to transplant
TR201903267T4 (tr) * 2014-10-15 2019-03-21 Alexion Pharma Inc Büyük ölçekli eculizumab üretim hücre kültürünün replikasyon metotları.
EP3288586A1 (en) * 2015-05-01 2018-03-07 Alexion Pharmaceuticals, Inc. Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of kindney thansplant
CA3027487A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
GB201911931D0 (en) * 2019-08-20 2019-10-02 Univ College Cardiff Consultants Ltd Anti-C7 antibody or antibody fragment
US20210353685A1 (en) * 2020-05-14 2021-11-18 Brain Cancer Research Institute Augmentation of Cell Therapy Efficacy by Inhibition of Complement Activation Pathways
CN114532982A (zh) * 2022-01-12 2022-05-27 高谋 评价干细胞系统移植调控补体活化作用的体系
US20240197816A1 (en) * 2022-12-08 2024-06-20 Novmetapharma Co., Ltd. Composition and method for prolong survival of transplant and recipient

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2588579B2 (ja) 1988-04-21 1997-03-05 株式会社クラレ 耐熱水性にすぐれたポリビニルアルコール系繊維およびその製造法
US5705732A (en) 1989-06-12 1998-01-06 Oklahoma Medical Research Foundation Universal donor cells
US5135916A (en) 1989-06-12 1992-08-04 Oklahoma Medical Research Foundation Inhibition of complement mediated inflammatory response
US5573940A (en) * 1989-06-12 1996-11-12 Oklahoma Medical Research Foundation Cells expressing high levels of CD59
GB9007971D0 (en) * 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
US20010018051A1 (en) * 1990-04-09 2001-08-30 White David James Graham Inhibition of allograft and concordant xenograft rejection
JPH06503344A (ja) * 1990-12-06 1994-04-14 ティーセル　サイエンシズ，インコーポレーテッド 可溶性の補体受容体と、補体を抑制しかつ／または免疫活性を抑制する化合物との相乗組成物
US5456909A (en) * 1992-08-07 1995-10-10 T Cell Sciences, Inc. Glycoform fractions of recombinant soluble complement receptor 1 (sCR1) having extended half-lives in vivo
US5308341A (en) 1993-09-28 1994-05-03 Becton, Dickinson And Company Method of testing the dose accuracy of a medication delivery device
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5679345A (en) * 1994-06-02 1997-10-21 The Johns Hopkins University Method for preventing complement-dependent rejection of organ or tissue transplants
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6355242B1 (en) * 1997-05-23 2002-03-12 Ixion Biotechnology, Inc. Materials and methods for treating or preventing oxalate-related disease
JP2002502824A (ja) 1998-02-04 2002-01-29 ザ・ジェネラル・ホスピタル・コーポレイション 同種移植における補刺激遮断および混合キメラ現象
US6302855B1 (en) 1998-05-20 2001-10-16 Novo Nordisk A/S Medical apparatus for use by a patient for medical self treatment of diabetes
AU1521000A (en) 1998-11-06 2000-05-29 Schepens Eye Research Institute, Inc., The Local use of soluble tumor necrosis receptor i (stnfri) for prophylaxis and treatment of corneal transplant rejection and other disorders of the eye
US6192891B1 (en) * 1999-04-26 2001-02-27 Becton Dickinson And Company Integrated system including medication delivery pen, blood monitoring device, and lancer
AUPQ431299A0 (en) 1999-11-26 1999-12-23 Unisearch Limited Method of inducing immune tolerance
WO2001057184A2 (en) * 2000-02-01 2001-08-09 Vanderbilt University Use of platelet activity modulators for inhibiting complement activation
EP2113516B1 (en) 2000-10-10 2014-05-21 Genentech, Inc. Antibodies against C5 inhibiting type II endothelial cell activation
ATE424893T1 (de) * 2001-06-08 2009-03-15 Novartis Pharma Gmbh Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung
ES2283594T5 (es) 2001-08-17 2016-03-15 Genentech, Inc. Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
EP1478354A4 (en) 2002-01-22 2008-09-24 Genzyme Corp USE OF TGF-BETA ANTAGONISTS IN THE TREATMENT OR PREVENTION OF CHRONIC RELEASE OF TRANSPLANT
WO2005025509A2 (en) * 2003-09-11 2005-03-24 Board Of Regents, The University Of Texas System Methods and materials for treating autoimmune diseases and conditions
US20050169921A1 (en) * 2004-02-03 2005-08-04 Leonard Bell Method of treating hemolytic disease
WO2005110481A2 (en) 2004-05-14 2005-11-24 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
CA2566861A1 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders

Also Published As

Publication number Publication date
US20090028850A1 (en) 2009-01-29
JP2007537299A (ja) 2007-12-20
IL179240A (en) 2014-07-31
DK1755674T3 (en) 2015-02-09
US20190309053A1 (en) 2019-10-10
IL179240A0 (en) 2007-03-08
CA2566716A1 (en) 2005-11-24
HK1201758A1 (en) 2015-09-11
AU2005244012A1 (en) 2005-11-24
ES2528362T3 (es) 2015-02-09
CA2566716C (en) 2014-12-23
JP5161567B2 (ja) 2013-03-13
HK1222342A1 (zh) 2017-06-30
EP3056218A1 (en) 2016-08-17
EP2338511A3 (en) 2012-07-25
WO2005110481A2 (en) 2005-11-24
JP2013032391A (ja) 2013-02-14
PT1755674E (pt) 2015-02-05
US20170267751A1 (en) 2017-09-21
JP5590624B2 (ja) 2014-09-17
AU2005244012B2 (en) 2011-08-18
AU2005244012B9 (en) 2011-11-03
EP2815767A1 (en) 2014-12-24
EP1755674B1 (en) 2014-11-19
AU2005244012C1 (en) 2013-05-02
HK1101962A1 (en) 2007-11-02
SI1755674T1 (sl) 2015-04-30
EP2338511A2 (en) 2011-06-29
IL233326A0 (en) 2014-08-31
NZ551308A (en) 2009-06-26
JP2014080438A (ja) 2014-05-08
EP1755674A2 (en) 2007-02-28
WO2005110481A3 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
IL179240A0 (en) Prolongation of survival of an allograft by inhibiting complement activity
IL193623A0 (en) Prolongation of survival of an allograft by inhibiting complement activity
GB2413769B (en) Ureteric stents
EP1939201A4 (en) NEW ADENINE CONNECTION
EP1732566A4 (en) 6-azaindole COMPOUND
IL183510A0 (en) Pyridazinone compounds
EP1798221A4 (en) NITROGENIC HETEROCYCLIC 2-ARYLCARBOXYLENEAMIDE COMPOUND
IL176942A0 (en) Imidazolo-5-yl-2-anilinopyrimidines as agents for the inhibition of cell proliferation
EP1961754A4 (en) BICYCLIC HETEROCYCLIC COMPOUND
AU157196S (en) Watch
AU2011236106B2 (en) Prolongation of survival of an allograft by inhibiting complement activity
IL165618A0 (en) Complementary masks
GB2421064B8 (en) Improved chamber
GB0520231D0 (en) Improved chamber
TWI317830B (en) Structure of back cover
GB2426775B (en) Chamber riser
PL369353A1 (pl) Zestaw elementów budowlanych
GB0400811D0 (en) Immunosuppressant
GB0422066D0 (en) Improved chamber
GB0412138D0 (en) Definition of zeroclick
ZA200702621B (en) Containment of produce
GB0407251D0 (en) Anti-tangle aid
GB0422950D0 (en) Fairing
AU301443S (en) Loading ledge
GB0406115D0 (en) Vox